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Though antihypertensive drugs have been in use for many decades, the mechanisms
by which they act chronically to reduce blood pressure remain unclear. Over long
periods, mean arterial blood pressure must match the perfusion pressure necessary
for the kidney to achieve its role in eliminating the daily intake of salt and water.
It follows that the kidney is the most likely target for the action of most effective
antihypertensive agents used chronically in clinical practice today. Here we review the
long-term renal actions of antihypertensive agents in human studies and find three
different mechanisms of action for the drugs investigated. (i) Selective vasodilatation of
the renal afferent arteriole (prazosin, indoramin, clonidine, moxonidine, α-methyldopa,
some Ca++-channel blockers, angiotensin-receptor blockers, atenolol, metoprolol,
bisoprolol, labetolol, hydrochlorothiazide, and furosemide). (ii) Inhibition of tubular solute
reabsorption (propranolol, nadolol, oxprenolol, and indapamide). (iii) A combination of
these first two mechanisms (amlodipine, nifedipine and ACE-inhibitors). These findings
provide insights into the actions of antihypertensive drugs, and challengemisconceptions
about the mechanisms underlying the therapeutic efficacy of many of the agents.
Keywords: antihypertensive drugs, renal circulation, hypertension, diuretics, vasodilator agents
INTRODUCTION
Why Is This Topic Currently Especially Important?
The long-term regulation of systemic arterial blood pressure is a topic beset with a remarkable
degree of controversy. Many textbooks teach that systemic vascular resistance (SVR) is the primary
factor in this long-term regulation (Pocock and Richards, 2006; Levick, 2010; Beevers et al., 2014),
a view that continues to be aired in peer-reviewed scientific journals (Averina et al., 2012; Pettersen
et al., 2014; Kurtz et al., 2015; Joyner et al., 2016). Some texts highlight the role of the kidney
in setting arterial blood pressure, emphasizing its role in determining the volume of fluid in the
circulation (Boron and Boulpaep, 2012; Mohrman and Heller, 2014). Sometimes these discordant
viewpoints are presented one following another without resolution (Steddon et al., 2007). The
confusion associated with this topic is important because extensive resources are directed toward
the diagnosis and treatment of hypertension, since sustained elevation of arterial blood pressure
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makes a very considerable and geographically variable
contribution to the global burden of mortality from non-
communicable diseases (Forouzanfar et al., 2015). Thus, for
example, a recent comparison between the USA, Canada and
England has shown high prevalences of hypertension, a strong
relationship between indicators of hypertension and both stroke
mortality and ischemic heart disease mortality, and rather
dramatic differences between these three countries (Joffres
et al., 2013). Recognition and management of hypertension
appear to be strongest in Canada, followed by the USA, followed
by particularly alarming figures for England. Given that the
therapeutic activity of antihypertensive drugs is to a large extent
empirical and may itself be associated with a variety of adverse
effects, clear targeting of relevant tissue components in whatever
organ system does regulate arterial pressure over long periods of
time, would be highly desirable.
That modulation of SVR is a major factor in determining the
long-term setting of arterial pressure is widely inferred from its
precise relationship with mean arterial pressure (MAP) via what
we can regard as Ohm’s Law for the systemic circulation:
(MAP− CVP) = Q˙× SVR, (1)
where CVP is central venous pressure and Q˙ is cardiac output.
Moreover, it is a common observation that Q˙ is often largely
unchanged in hypertension, whilst CVP is small in relation to
MAP, and also often largely unchanging. Equation (1) inclines
us to think in terms of MAP as being almost mathematically
proportional to SVR, and hence to consider SVR as being a
major determinant of MAP. The common usage that variables
on the left-hand side of an equation are dependent variables,
whilst those on the right-hand side are independent variables, has
tended to reinforce this emphasis.
An alternative view is that it is more helpful to think of
Equation 1 in a rearranged form:
Q˙ = (MAP− CVP)/SVR, (2)
where MAP is determined slowly over time by the need for
the circulation to be in “mass balance” (a view expanded on
below), and SVR is set by many known (and as yet unknown)
structural, neural, humoral, and pharmacological factors. In this
approach Q˙ (and CVP) are viewed as the dependent variables
that are constrained by a need to satisfy this strict physiological
relationship, as well as the properties of the heart known as the
“Frank-Starling” relationship between Q˙ and CVP. This is the
view taken by some authors giving what we may think of as a
“descriptive” account of physiological measurements (Hall, 1999;
Montani and Van Vliet, 2009; Ivy and Bailey, 2014). It is also
the view to which authors using theoretical mathematical models
of the circulation have found themselves driven (Guyton, 1980,
1987; Keener and Sneyd, 2009; van den Berg, 2011).
Several associations between SVR and MAP make it difficult
for researchers and healthcare workers to form a clear view
about cause and effect. First, SVR is indeed typically raised in
hypertension—an association that does not necessarily imply
direct causation. Secondly, it seems likely that the physiological
processes that commonly lead to changes in the kidney and
its vasculature, which may be the direct cause of hypertension,
concurrently elevate SVR by affecting blood vessels throughout
the body. Thirdly, many drugs that act on the kidney to
ameliorate hypertension also act on the wider circulation to lower
SVR. Fourthly, short-term changes in arterial blood pressure
are very commonly brought about by changes in SVR, either
spontaneously or therapeutically. A truly integrative approach
is needed to separate causation from association, and thus the
topic provides an outstanding educational challenge as well as a
scientific battlefield.
The aim of this paper is both educational and scientific. We
give the basis for the view that renal mechanisms regulate arterial
blood pressure on a time scale of days to years. We then review
what is known about how antihypertensive drugs act upon the
kidney to achieve a sustained reduction in arterial pressure. This
enables a clear distinction to be drawn between the incidental
effects these drugs have elsewhere on the body, which may be
harmful or beneficial, and their primary therapeutic renal actions
in hypertension.
Short-Term vs. Long-Term Regulation of
Arterial Blood Pressure
A considerable variability of arterial blood pressure obtained
from one measurement to another over short periods of time
is widely observed in patients and healthy individuals, even at
rest (Littler et al., 1978; deBoer et al., 1987; Rothwell, 2010).
Perhaps more than physicians in any other specialty, anesthetists
are familiar with exaggerations of normal changes; it is not
uncommon to see the rapid halving or doubling of arterial blood
pressure in response to drugs such as anesthetics, vasodilators,
and catecholamines, as well as to surgical events. Short-term
lability of blood pressure can be thought of as resulting from
rapid changes in SVR, vascular compliance, cardiac contractility,
heart rate, and (in the presence of bleeding or infusion)
circulating volume. The interplay of these factors, when precisely
defined, enables MAP to be modeled in what might be regarded
as a closed circulation (Dorrington and Pandit, 2009; Keener and
Sneyd, 2009).
Amidst the “noise” of short-term variations in blood pressure
it is easy to lose sight of the constraint imposed upon the
circulation that engineers call “mass balance.” Over prolonged
periods of time the inputs of salt and water to the circulation
must match their output. Since the kidney provides the main
regulated route for excretion of salt and water, the pressure in
the arterial tree must equilibrate over time with the pressure
required by the kidney to perform this ongoing task. Taking this
view of an open circulation it follows that MAP over prolonged
periods is determined by one “final common path”—to use
the term Sherrington (Sherrington, 1920) gave to the lower
motor neuron of the nervous system—in this case the kidney
(Dorrington and Pandit, 2009; Keener and Sneyd, 2009; van den
Berg, 2011). This pressure will be a factor not only of the intrinsic
structure of the kidney; it will be affected by neural, humoral, and
pharmacological regulators of renal function; here we assess this
latter group.
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It is important to appreciate that what is both approvingly
and sometimes dismissively called the “Guyton model” of long-
term blood pressure control, following determined advocacy
by Arthur Guyton over many years (Guyton, 1980, 1991), is
fundamentally an expression of mass balance in the circulation,
and might be less controversially named as such. Perhaps a
term such as a “physical equilibrium model” would carry less
historical baggage for some workers in the field, whilst others
continue to see the eponymous attribution as giving due credit to
a distinguished physiologist. The equilibrium has probably been
depicted in its most simple and accessible analogy by Kimura
et al. who depicted arterial blood pressure as the height of
liquid in a water tank, from which the only elimination was
via an outflow pipe representing the kidney (Kimura et al.,
1986). This model was later used to examine the hypotensive
actions of different families of drugs in a strikingly perceptive
manner (Kimura et al., 1989) and to clarify the sensitivity of
high blood pressure to daily sodium excretion (Kimura et al.,
1990).
How Can the Kidney Do the Same Job at a
Lower Arterial Pressure?
Two main ways can be envisaged in which drugs may permit
the kidney to continue to eliminate the normal daily intake of
salt and water whilst being perfused from an arterial tree at
a reduced pressure: either a vascular or a tubular mechanism.
Exchange of water and solutes across any epithelium is a function
of the “Starling forces,” the hydrostatic and osmotic pressure
differences across the epithelium, and the vigor of actively-
driven cellular transport mechanisms that act to modify the
osmotic pressures. The interrelation between these determinants
of transepithelial flux has been widely explored in relation to
the kidney (Martino and Earley, 1968; Knox et al., 1983) and
can also be demonstrated in other epithelia such as those in
the intestine (Mailman, 1982) and the lung (Vejlstrup et al.,
1994).
Perhaps the simplest way for a vasoactive drug to permit the
kidney to perform its normal handling of salt and water at a
reduced MAP is via dilatation of the afferent arteriole leading to
the glomerulus. Isolated afferent arteriolar vasodilatation could
allow the glomerular capillaries to be perfused at an unchanged
pressure in the presence of a low MAP. This could maintain an
unchanged glomerular filtration rate (GFR) and an unchanged
renal blood flow (RBF), whilst a measurement of renal vascular
resistance (if defined as MAP/RBF) would show it to have
decreased. Such an intervention would be analogous to the
surgical removal of a renal artery stenosis, a classic example of
“secondary hypertension,” eliminating an excessive pressure drop
across the vessels entering the kidney, so that from the glomerular
capillaries onwards nothing is different after the intervention
when compared with before the intervention. It will become clear
that the actions of several families of drugs converge on this
common pathway.
The “non-vascular” route to modifying the pressure at which
the kidney operates involves the inhibition of active Na+
and other ionic reabsorption from the renal tubule into the
peritubular capillaries: a tubular, epithelial, mode of action.
Inhibition of the active component of reabsorption has to
translate into a readjustment of Starling forces to maintain
reabsorption and keep the body in sodium and water balance.
This in turn requires a lower hydrostatic pressure in the
peritubular capillaries and throughout the renal vascular bed,
including the glomerular capillaries. Some antihypertensive
drugs are associated with a reduction in GFR and appear to have
their main renal action on inhibition of active Na+ and water
reabsorption, and the consequent resetting of the Starling forces
across the tubular epithelium. A review of the literature leads to
surprises in this area.
If an antihypertensive can be associated with a fall in GFR,
under what circumstances may one be associated with a rise in
GFR? In fact, a large family of drugs is capable of bringing about
an increase in hydrostatic pressure gradient along the efferent
arteriole of the kidney, generated either by an increased resistance
in, or a higher blood flow through, these vessels. These drugs
achieve marked afferent arteriolar dilatation with a degree of
inhibition of active tubular reabsorption, combining a vascular
action with a tubular action.
A HISTORICAL PERSPECTIVE ON
METHODOLOGY
Measurement of Renal Hemodynamics in
Humans
We are fortunate in having two sound, long-standing methods
for measuring RBF and GFR in humans. Both rely on measuring
“renal clearance.” The clearance of a substance in the blood
is the volume of blood from which the substance can be
regarded as having been completely eliminated in unit time,
and is therefore measured in units such as ml/min. A small
derivative of glycine, para-aminohippurate (PAH), is both filtered
at the renal glomerulus and secreted in the renal tubule.
This almost complete removal of PAH from blood passing
through the kidney leads to its renal clearance being a measure
of RBF (Chasis et al., 1945). Inulin is a polysaccharide that
is filtered at the glomerulus whilst being neither secreted
nor absorbed by the renal tubule in any appreciable amount
(Shannon and Smith, 1935). It follows that its renal clearance
is a measure of GFR, long seen as an indicator of the extent
to which the kidney is functioning satisfactorily. Some studies
use the clearance of the endogenous molecule creatinine as an
approximation to the GFR (Preston et al., 1979), as in clinical
practice.
Since GFR is determined in part by glomerular capillary
pressure (Pglom) there has been much interest in attempting
to measure Pglom and observe changes in these variables
associated with essential hypertension and with antihypertensive
medication. Unfortunately, direct measurement of Pglom has not
proved possible in humans, and researchers remain dependent
upon the approach of Gómez published over half a century
ago (Gomez, 1951). We briefly summarize this approach in the
following section, because its limitations need to be taken into
account.
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Estimation of Glomerular Capillary
Pressure
Domingo Gómez derived Pglom from measured GFR by
assuming a “normal” value from the literature of the glomerular
permeability coefficient (taking into account body size), which
we here write as K, and writing the Starling relationship for
glomerular filtration as follows:
GFR = K(Pglom − Ptub −5), (3)
where Ptub is the hydrostatic pressure in Bowman’s space (and
the whole renal tubule) and 5 is the oncotic pressure of plasma.
Ptub is commonly assumed in humans to be similar to that
measured directly in other mammals (Ichikawa and Brenner,
1980; Bencsath et al., 1983) and to equal 10–15 mmHg, and 5
is calculated from plasma protein concentration using various
formulae; estimations of 5 are usually close to 25 mmHg
(Bencsath et al., 1983). Estimates of Pglom are commonly close
to 60 mmHg with the net filtration pressure around 60 − 10 −
25 = 25 mmHg. In 22 normotensive humans, Gómez estimated
a mean value for Pglom of 63 mmHg (derived from Gomez,
1951, Table 1). Figure 1 illustrates the pressure profile in the
blood vessels passing through the kidney, based in part on direct
measurement of pressures in animal preparations (Carmines
et al., 1990).
Of special interest in relation to hypertension is the question
of whether a major contributor to the condition is an abnormally
elevated afferent arteriolar resistance (RA), defined as the
resistance of blood vessels between the large arteries and the
glomerular capillaries:
RA = (MAP− Pglom)/RBF. (4)
The behavior of the efferent arteriole leaving the glomerulus is
also of interest because its resistance RE relative to RA plays
FIGURE 1 | The profile of hydrostatic pressures along the renal
vasculature, showing typical normal values. MAP, mean arterial pressure;
Pglom, glomerular pressure; Ppc, peritubular capillary pressure. The large
arrow labeled “Filtrate” is a cartoon representation of the flow of glomerular
filtrate, most of which is reabsorbed from the tubule into the peritubular
capillaries. The small fraction of the filtrate that is not reabsorbed is depicted
by the arrow labeled “Urine.”
a role in determining both RBF and Pglom. Here the analysis
meets difficulties; another unknown is the mean pressure in the
peritubular capillaries Ppc, downstream of the efferent arteriole,
which is required for a calculation of RE:
RE = (Pglom − Ppc)/(RBF− GFR). (5)
Note that in this equation the flow of blood through the efferent
arterioles is now RBF minus the flow of the glomerular filtrate, a
flow diverted past the efferent arteriole via the renal tubule; this
flow is represented in cartoon form in Figure 1 by the large arrow
labeled “Filtrate.”
Gómez took the view that the surface area of the peritubular
capillaries was likely to be so much greater (by 15–60 fold) than
that of the glomerular capillaries that the net filtration pressure
across the tubule-capillary barrier would be approximately zero.
This can be expressed as:
Ppc ≈ Ptub +5, (6)
yielding pressures in the peritubular capillaries of around 35
mmHg. If Equation (6) is taken as precise, a combination of
Equations (3, 5, and 6) then gives:
RE = GFR/(K(RBF− GFR)). (7)
Some authors prefer to complete the picture of renal vascular
behavior by including the venular resistance, defined as:
RV = (Ppc − Pv)/RBF, (8)
where Pv is the pressure in the renal veins, commonly assumed
to be around 10 mmHg. Clearly, there is an assumption here that
the urine flow is so small in comparison with RBF that it can be
ignored from the calculation of the resistance of the venules. The
small fraction of the filtrate is labeled “Urine” in Figure 1.
Venular pressure can be measured in humans directly by
passing a catheter into the renal veins. In 1970, Lowenstein
et al. developed the technique of advancing a 0.9 mm diameter
polyethylene catheter from the renal vein (where a typical Pv
was ∼6 mmHg) until it wedged in a smaller vein and recorded
a pressure taken to be that of the peritubular capillaries, Ppc
(Lowenstein et al., 1970). Their estimates of Ppc from this
“renal vein wedge pressure” varied considerably between normal
individuals in the approximate range 20–30 mmHg following
a period of 12–16 h of fluid restriction. Higher values were
obtained in hypertensives and in all volunteers during diuresis
following infusions of saline or mannitol. Using the same
technique, Willassen and Ofstad later measured Ppc to be ∼25
mmHg in fasted healthy volunteers and hypertensives, with
values of Pv close to 2 mmHg (Willassen and Ofstad, 1980).
These data from humans suggest that Gómez’s estimate of 35
mmHg for Ppc is rather high, and that there may normally be a
substantial gradient in Starling forces driving reabsorption into
the peritubular capillaries, such that Ppc < (Ptub + 5) by a
substantial number of mmHg. Direct puncture measurements in
small mammals have tended to suggest this too. Ichikawa and
Frontiers in Physiology | www.frontiersin.org 4 July 2016 | Volume 7 | Article 320
Digne-Malcolm et al. Renal Antihypertensive Actions of Drugs
FIGURE 2 | Pressure–natriuresis lines for eight hypertensive adult
patients before (open circles) and after (closed circles) administration
of a thiazide diuretic (mefruside 25mg daily). Urinary sodium excretion
rate was measured after several periods of 7 days of constant daily sodium
intake of between 1 and 18g NaCl and systemic mean arterial pressure
plotted as a function of sodium excretion. Data from Saito and Kimura (1996).
Note that the untreated hypertensive patients showed a marked dependence
of mean arterial pressure (MAP) on sodium excretion, whilst thiazide
administration reduced this dependence and also lowered MAP.
Brenner, using direct puncture measurements in rats, found that
both Ppc and Ptub were close to 15 mmHg whilst 5 was ∼25
mmHg, suggesting a net reabsorption Starling pressure between
the tubule and peritubular capillary of about 25 mmHg (Ichikawa
and Brenner, 1980), a net Starling “force” similar to that driving
glomerular filtration. The estimate of RE given by Equation (5)
then becomes an underestimate of the true value by of the order
of 50%.
Renal Hemodynamic Changes Observed
by Gómez in Hypertensive Patients
Gómez proceeded to examine the magnitudes of RA, RE,
and RV in 22 healthy subjects and in 46 patients with
essential hypertension (Gomez, 1951). A striking difference was
observed between the two groups. In the healthy subjects, the
three vascular resistances were approximately equal. In the
hypertensive patients the prominent finding was that RA was
five times greater than in the healthy subjects. In 16 of the
hypertensive humans, Gómez measured a mean value for Pglom
of 47 mmHg (his Table 2). Interestingly this is somewhat lower
than the value he found for normotensives (63 mmHg).
He went on to draw a conclusion about the relative
magnitudes in the hypertensive patients of SVR and RA. He
noted that RA tended to correlate with SVR in a pattern in which
a doubling in SVR was associated with an approximate 5-fold
increase in RA. This early analysis pointed strongly toward an
abnormally intense increase in RA as the defining feature of
essential hypertension. It appeared that some mechanism was
capable of increasing arteriolar resistance throughout the body,
but was unusually potent in its effects on the renal afferent
arterioles (Coleman et al., 1975).
The Gómez formulae have been widely used (Preston et al.,
1979; Inigo et al., 2001; Delles et al., 2003; Ott et al., 2013).
Interestingly, they were derived before the processes of active
tubular epithelial transport were elucidated by Koefoed-Johnsen
and Ussing (1958). By 1951 it was already recognized that
glomerular filtration was a form of passive ultrafiltration driven
by Starling forces and that renal tubular uptake was characterized
by some form of active “specific absorbing mechanisms for the
separate ions” (Krogh, 1946) modulating the ubiquitous Starling
forces. In the light of this, the model of Gómez has to be
interpreted as subsuming any such active transport within the
cautious assumption expressed in Equation (6) of, on average
along the tubule, Starling forces across the tubule-capillary wall
of no more than a few mmHg. We have noted above a weakness
of this assumption and the probability that there may be a
considerable gradient of Starling forces of ∼25 mmHg driving
reabsorption despite the presence of transcellular active solute
transport. We now know much detail about active transport
processes in the different segments of the renal tubule, in some
regions of which there may be low permeability to water and
consequently a gradient in Starling forces. It remains striking,
however, that a reviewer of fluid transport by epithelia as recently
as 2008 should have to write that “despite a voluminous literature,
however, there is no clear idea of how it occurs” (Hill, 2008).
Both in relation to Gómez’s original assumptions in 1951, and
the subsequent expansion of our knowledge about active tubular
transport, we are left with continued uncertainty about the
precision with which RE and RV can be separately obtained in
humans using the above formulae.
Kimura’s Method of Estimating Glomerular
Capillary Pressure
An alternative approach to the measurement of RA has been
proposed by Kimura et al. (1991b). Thirty hypertensive patients
were studied over a 2-week period on a regular sodium diet
(intake 223 meq/day) for 1 week and then on a low sodium
diet (intake 30 meq/day) for 1 week. Values of MAP measured
after each of these weeks were respectively 120 mmHg and 109
mmHg. A renal pressure-natriuresis line (sometimes called a
“renal function curve”) was plotted using these two data points
and extrapolated to obtain the hypothetical MAP at which
sodium elimination would be zero, MAPo. These investigators
found MAPo to be 107 mmHg, and argued that, since reduction
in MAP from its normal value on a regular diet (120 mmHg)
to MAPo would result in cessation of renal sodium clearance,
MAP − MAPo must equal the net filtration pressure across
the glomerular capillaries (Pglom − Ptub − 5) whilst on the
normal diet. For the group of patients as a whole, application of
this approach predicted mean values of Pglom and RA that were
respectively 7% lower and 6% higher than those obtain using
Gómez’s formulae. An important advantage of the approach
of Kimura et al. is that no assumption needs to be made
about the value of the glomerular permeability coefficient, K. A
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significant drawback, however, is the complexity and duration of
the experiments required, including the compliance of patients
with a low sodium diet for at least 1 week. Comparison of
the results from the two approaches suggests that they both
provide satisfactory means for estimating Pglom and RA, but
the estimation of RE and RV remains problematic, for reasons
discussed above. Rat experiments have shown a fair agreement
between values of Pglom obtained using the pressure-natriuresis
extrapolation and direct puncture of glomerular capillaries
(Kimura and Brenner, 1997). As Gómez had found much earlier,
Kimura et al. concluded that the hypertension in their patients
was characterized by very high values of RA in the presence of
relatively normal values of both Pglom and RE. They subsequently
applied their methodology to examining the renal hemodynamic
effects of the antihypertensive drug nicardipine (Kimura et al.,
1991a).
Despite difficulties estimating Ppc, RE, and Rv in human
studies, the relationship between GFR and Pglom expressed
in Equation (3) remains well established, and allows some
confidence in concluding that human studies demonstrating a
rise or fall in GFR in individuals to whom antihypertensive
drugs are administered are experiencing a corresponding rise or
fall, respectively, in Pglom. We make use of this assumption in
deducing changes in the hydrostatic pressure profile along the
renal vasculature.
What the Pressure-Natriuresis Line Tells us
about Renal Hemodynamics
Kimura and colleagues examined the pressure-natriuresis
relationship for eight hypertensive patients using exposure to
three different values of sodium excretion to assess to what extent
they could regard the relationship as linear (Saito and Kimura,
1996). Figure 2 shows the result. Though based only upon three
data points (each taken after 1 week on a regulated sodium
intake) the relationship appears linear. A striking feature is that
MAP increases greatly with sodium intake/excretion over the
approximate 10-fold range. Note the intercept at zero sodium
excretion of 104 mmHg, similar to the value of 107 mmHg
referred to above in relation to another set of (30) hypertensive
patients.
We have already noted the concept that this intercept gives
information about the net filtration pressure at the glomerulus,
implying that, if the intercept were to remain unchanged during
administration of a drug, then for any given value of MAP
the value of Pglom would be the same with or without the
drug. Figure 2 contains data obtained from the same patients
under the condition of taking the antihypertensive thiazide-like
diuretic mefruside. The authors found no statistically significant
difference between the intercepts with and without mefruside,
whereas the slope of the relationship was changed significantly
(p< 0.005). Mefruside moved the line toward the horizontal and
lowered MAP over the range of sodium intakes.
It is interesting to consider what the significance would have
been were a drug like mefruside able to render the line completely
horizontal so that MAP became independent of sodium intake.
Following the approach of Gómez given earlier, this would imply
that the net filtration pressure across the glomerular capillaries
(Pglom − Ptub − 5) was approximately zero and that Pglom was
close to (Ptub+ 5), which is commonly taken to equal 35mmHg.
If the imaginary drug were capable of inhibiting all active
reabsorption of solutes from the renal tubule, we would then
have a situation where the filtered sodium load entering the renal
tubule from the glomerulus in a very low GFR (requiring only a
small net glomerular filtration pressure) was all lost in the urine!
In this light, it may seem surprising that the normal healthy
pressure-natriuresis line is indeed fairly flat, as has been seen in
four-data-point plots obtained from dogs (Hall et al., 1980) and
using three- or two-data-point plots in healthy humans (Parfrey
et al., 1981a,b; Fukuda and Kimura, 2006). Indeed, the flatness
of the relationship in health is a remarkable reflection of how the
neural, humoral, or intrinsic regulation of the kidney is capable of
permitting large changes in the renal elimination of salt without
there being a large change in MAP. Bie has noted that modest
acute body loading with sodium (over 2–3 h) can lead to a
rapid substantial change in renal sodium excretion rate without
a change in MAP, and that this phenomenon is strong evidence
either for a vigorous macular densa tubulo-glomerular feedback
mechanism, or for a further, as yet unidentified, regulator of renal
function (Bie, 2009). Whether the mechanisms regulating these
short-term responses are also those acting in the longer term
remains to be seen.
After analyzing the effects of different families of drugs on
renal hemodynamics in the sections below, we shall be in
a position to assess this apparent inconsistency of mefruside
yielding a fairly flat pressure-natriuresis line, and also explore
those situations in which antihypertensive drugs leave the
gradient of the pressure-natriuresis line unchanged, and when
they canmake it steeper.We shall see that the pressure natriuresis
line provides information that could usefully guide therapy if
it were to be more widely available and its significance better
understood.
Overview of Renal Hemodynamic
Abnormalities That May Lead to
Hypertension
Before surveying the literature for the renal hemodynamic effects
of long-term antihypertensive medication it may be helpful to
summarize what kind of abnormalities might have the potential
to induce hypertension in the first place. We have alluded already
to increased pre-glomerular resistance, and noted Gómez’s early
striking observation of this phenomenon in individuals with
essential hypertension (Gomez, 1951), which has been confirmed
by others (Kimura et al., 1991b). The possibility of a reduction
of the glomerular permeability coefficient K (Equation 3) in
some kinds of hypertension appears to lead to high Pglom and
thereby high MAP (Sanai and Kimura, 1996), and is discussed
further below in relation to mesangial cells. Loss of functional
nephrons, an inability to modulate the renin-angiotensin-
aldosterone system appropriately (Hall et al., 1980), and the
various genetic abnormalities of renal tubular sodium uptake
(Kurtz et al., 2015) are all material, even though their precise
mode of influencing blood pressure may remain uncertain.
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RESULTS FROM THE LITERATURE
We surveyed the literature for studies in healthy humans
and patients with hypertension in which measurements of
arterial blood pressure and renal hemodynamics had been
made in the control condition of no drug therapy and
following a minimum of 1 week of sustained drug therapy.
We included only those in which a statistically significant
fall in MAP (or both systolic and diastolic pressure) had
been found on drug therapy. In the tables below we present
statistically significant changes in renal hemodynamic variables
or indicate no change. A point of note arises in relation to
the overall RVR defined and calculated by most authors as
follows:
RVR = MAP/RBF. (9)
In some studies, no statistically significant change in either
RBF or RVR was found, despite the fall in MAP. To help
with data interpretation, such apparently anomalous findings
are indicated in the tables with a footnote to explain the
anomaly.
Our on-line search strategy was to use Web of ScienceTM,
entering the names of specific agents or drug classes, and linking
these, in turn, with the terms “renal hemodynamics” (in UK and
USA spelling), “glomerular filtration rate,” “renal blood flow,”
and “renal plasma flow.” We surveyed titles and abstracts to
select human studies on both healthy volunteers and patients
with hypertension that was found not to be attributable to
secondary (known) causes. Reference lists from publications
identified in this way were surveyed for further relevant
publications.
Vasodilators
Table 1 summarizes renal hemodynamic measurements of
drugs classically regarded as “vasodilators.” This table includes
information for α1-blockers (prazosin, indoramin), an α2-agonist
(clonidine), an imidazoline I1 receptor agonist (moxonidine),
α-methyldopa, and Ca++-channel blockers (CCBs) (verapamil,
diltiazem, manidipine, nicardipine, nitrendipine, isradipine,
amlodipine, and nifedipine). Where measured, these studies
invariably show a fall in RVR or RA, usually in the presence of
an unchanged RBF; the exceptions to the latter were diltiazem,
nifedipine, nitredipine, and isradipine, which showed an increase
in RBF. With regard to GFR, most studies found no change,
but a rise was noted in three studies involving nifedipine and
amlodipine. The families of agents represented in Table 1 thus
act primarily by achieving a sufficient degree of afferent arteriolar
vasodilatation to permit the kidney to maintain blood flow and
GFR despite a lower MAP. An unchanged GFR is consistent
with an unchanged Pglom for the reasons discussed above. The
associated profile of the renal vascular hydrostatic pressure
resulting from this mechanism of drug action is depicted in
Figure 3.
The suggestion of a raised GFR during treatment with
certain CCBs prompted some researchers to estimate Pglom
and the individual changes in RA and RE following chronic
administration of these agents. The several findings with
amlodipine, and single studies with two other drugs of this class,
suggested that an unchanged or elevated RE may be associated
with a rise in Pglom and a rise in GFR. A single study (of diltiazem)
found a marked reduction in both RA and RE, accompanied by a
rather distinctive fall in Pglom in the presence of unchanged GFR
and a large rise in RBF (Isshiki et al., 1987). Non-human studies
have suggested that a differential distribution of Ca++ channel
subtypes between the afferent and efferent arterioles may be able
to account for these effects (Hayashi et al., 2007), and have shown
similar differential effects on the two vessel types. For example,
acute administration of nifedipine to anesthetized dogs generated
a 27% fall in RA whilst leaving RE unaffected (Heller andHoracek,
1990), whilst acute administration of diltiazem to spontaneously
hypertensive rats reduced RA by 40% and RE by 18% (Isshiki
et al., 1987).
β-Blockers
Table 2 summarizes human renal hemodynamic measurements
obtained following administration, for at least a week, of
β-blockers. Here we see a pattern of behavior for the non-
selective agents propranolol and nadolol that act at both β1
and β2 receptors that is distinctively different from the agents
in Table 1. RBF is commonly reduced by drug administration,
RVR is unchanged or even elevated, and GFR never raised, but
often found to be reduced. This remarkable finding is perhaps
analogous to a reduction in renal tissue, and yet it remains
consistent with a normal daily elimination of sodium and water.
To reconcile these observations, it is clear that the proportion
of sodium and water reabsorbed from a reduced glomerular
filtrate must be reduced. A likely candidate mechanism would
be inhibition of active components of tubular reabsorption.
Unfortunately, we lack measurements in humans on long-term
antihypertensive medication that would allow us to understand
better the mechanism underlying this interesting effect of non-
selective β-blockers. Figure 4 depicts a profile of renal vascular
pressures consistent with the observations made in these studies.
The selective antagonists at β1 receptors, atenolol, metoprolol,
and bisoprolol show a different behavior. Most studies of
these agents in Table 2 show a contrasting fall in RVR.
Findings for RBF are variable. In these respects we see a renal
hemodynamic pattern similar to that of the α1-blocker prazosin,
the prominent feature being an afferent arteriolar vasodilatation
that is sufficiently great to permit the kidney to run at a lowered
arterial pressure with indices of RBF and GFR changing little, if at
all. The notion of a β1 antagonist having a primary vasodilatory
action is an unfamiliar concept; SVR is unchanged or increased
by β-blockers (Dreslinski et al., 1982; van den Meiracker et al.,
1989).
Labetolol is thought of as having antagonist activity at α-
receptors that exceeds its antagonist action at β-receptors. The
observations shown in Table 2 for this drug are consistent with
this picture, though the rise in RBF is a feature of only one other
of the several studies in Tables 1, 2 of α-blockers and β-blockers,
namely that by O’Callaghan et al. on atenolol (O’Callaghan
et al., 1983). Atenolol and labetolol have characteristics that
earn them a place in Figure 3 amongst a variety of drug
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TABLE 1 | The change in human renal hemodynamics after long-term vasodilator treatment for hypertension.
Vasodilators
Drug References RBF/RPF Pglom GFR FF RVR Duration (weeks) Participant number
Prazosin Koshy et al., 1977 = = 8 14
Preston et al., 1979; Warren et al., 1981 = = = RA: 4 10 males
†
RE: =
RV: =
O’Connor et al., 1979 = = = 4 12 males
Bauer et al., 1984b = = = 3–6 14
Anderton et al., 1994 = 10 14
Indoramin Bauer et al., 1984a = = = 3–6 11 males
Clonidine Cohen et al., 1979 = = = 4 13
Thananopavarn et al., 1982 = = 12 16
Golub et al., 1983 = = 1 16
= = 12 As above
Moxonidine Fauvel et al., 1998 = = = 4 20
α-Methyldopa Weil et al., 1963 = = 1–3 9
Mohammed et al., 1968 = = 1 8
Grabie et al., 1980 = 1 8
Verapamil Leonetti et al., 1980 = 1.5 12
Sorensen et al., 1985 = = = 6 11
Katzman et al., 1990 = = 8 15
Diltiazem Isshiki et al., 1987 = RA: 52 7
RE:
Sunderrajan et al., 1987 = = = 8 18
Manidipine Ott et al., 2013 = = = RA: 4 54
RE:
Nicardipine Smith et al., 1987 = = 6 6
Kimura et al., 1988 = 1 8
Kimura et al., 1991a = = = RA: 1 8
RE: =
Nitrendipine Thananopavarn et al., 1984 = = 2 10 males
Scaglione et al., 1992 = = 8 13
Isradipine Persson et al., 1989 = 9 20 males
Amlodipine Ranieri et al., 1994 = = = 12 18
Inigo et al., 2001 = = RA: * 6 17 (renal transplant recipients)
RE: =
Delles et al., 2003 = RA: 8 29
RE:
Ott et al., 2013 = = RA: 4 50
RE:
Nifedipine Olivari et al., 1979 = 3 27
Guazzi et al., 1984 = 1 14
Reams et al., 1988 = 4 26
Participants are individuals with essential hypertension unless otherwise specified. RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction;
RVR, renal vascular resistance; , significant decrease from control; , significant increase from control; =, no significant change from control; RA, afferent arteriolar resistance; RE ,
efferent arteriolar resistance. *Discrepancy between reported result in the text and in the results table—mistake in decimal point placement in results table assumed (Inigo et al., 2001).
†
Identical data in two publications, one stating n = 10 and one n = 12.
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FIGURE 3 | The actions on the hydrostatic pressure profile along the
renal vasculature of drugs that primarily dilate the afferent arterioles
and leave glomerular filtration rate, glomerular capillary pressure
(Pglom), and pressures downstream of the glomerular capillaries
unchanged. MAP, mean arterial pressure; Ppc, peritubular capillary pressure.
families that have a primary vasodilatory action on the afferent
arteriole.
ACE Inhibitors and AR Blockers
Table 3 summarizes renal hemodynamic measurements
following administration, for at least a week, of drugs inhibiting
the renin-angiotensin system. Amongst the angiotensin
converting enzyme (ACE) inhibitors, the usual pattern of
response is for RVR to fall sufficiently to permit a rise in RBF in
the presence of a lower MAP, and for this often to be associated
with an increase in GFR. Unfortunately, estimates of Pglom are
not available, but it is not unreasonable to assume, for reasons
given above, that a rise in Pglom is driving the increase in GFR.
The sparse data on angiotensin receptor (AR) blockers
suggests a slightly different pattern similar to most of the drugs
in the vasodilator group of Table 1, namely with a fall in RVR
or RA, with RBF maintained unchanged. These drugs appear to
be best depicted by Figure 3, but show some similarity with the
ACE inhibitors with respect to a lowering of filtration fraction
in some studies. For both kinds of agents in Table 3, there is
a suggestion that filtration fraction may be decreased. In other
words, the proportionate rise in RBF is tending to be even greater
than that of GFR.
For the increased GFR associated with the ACE-inhibitors
to exist in the presence of a presumed unchanged sodium and
water balance for the body as a whole, tubular reabsorption
of sodium and water must be enhanced to counter the excess
flux of filtrate. Given that these drugs are associated with an
inhibition of the action of angiotensin II and aldosterone on
sodium uptake by the proximal and distal tubules respectively,
this finding suggests that the enhanced reabsorption is driven
by a dominant increase in the passive Starling forces moving
filtrate across into the peritubular capillaries. This would require
a lower hydrostatic pressure in the peritubular capillaries
during drug therapy, which would in turn require a greater
pressure drop across the efferent arterioles, as blood passed from
the glomerular into the peritubular capillaries. The different
roles of the afferent and efferent arterioles in the action of
this family of drugs are particularly striking. Figure 5 depicts
a profile of renal vascular pressures consistent with these
observations.
Diuretics
Table 4 summarizes renal hemodynamic measurements
following administration, for at least a week, of diuretic drugs.
These drugs suffer from having a misleading family name;
whilst acutely they induce a diuresis, familiar to all patients
taking them, over a long period of administration the body
remains in sodium and water balance without a net diuresis.
The study of van Brummeln et al. over 9 months of therapy
with hydrochlorothiazide in 10 hypertensives found that 24-h
urinary sodium excretion remained unchanged, except at the
1-week point, where it was significantly lower than before
treatment (Van Brummelen et al., 1979). In the same study a
twice-daily regimen of furosemide administration was associated
with a cycle of 6-h diureses following drug ingestion and
6-h periods of reduced urine output before the next dose.
Overall there was no change in 24-h sodium excretion. The
possibility that long-term diuretic therapy might lead to a
prolonged increase in daily sodium flux, with a corresponding
increased daily sodium intake to maintain equilibrium, appears
to be excluded by this and another prolonged study (Roos
et al., 1981). Similarly, maintenance of 24-h sodium excretion
has been observed with other antihypertensives, including
prazosin (Koshy et al., 1977) clonidine (Thananopavarn
et al., 1982; Golub et al., 1983), moxonidine (Fauvel et al.,
1998), propranolol (O’Connor and Preston, 1982), nadolol
(O’Connor et al., 1982), amiloride (Matthesen et al., 2013), and
spironolactone (Matthesen et al., 2013). Having said this, an
increase in 24-h sodium excretion has been reported with both
hydrochlorothiazide (O’Connor et al., 1981) and metoprolol
(Sugino et al., 1984).
The pattern of diuretic behavior seen in Table 4 is the same
as for most of the “vasodilator” family seen in Table 1, with
the exception of the thiazide-like drug indapamide. A fall in
MAP is associated with no change in RBF or GFR. A fall
in RVR, when calculated, reflects this maintenance of normal
flows in the presence of a reduced perfusion pressure. Whilst
we commonly associate the actions of the different families
of diuretic drugs with inhibition of various different sodium
reabsorption mechanisms in the renal tubule, here the dominant
feature is their apparent vasodilatory potential in the afferent
arteriole. Figure 3 best represents the evidence from these studies
as an action of renal afferent vasculature leaving Pglom and
Ppc unchanged. If a lowering of Ppc is required to overcome a
degree of inhibition of active sodium reabsorption by these drugs,
interestingly this seems not to translate back upstream into a
lowering of Pglom, given that GFR remains unaltered by these
drugs. The exception to this pattern is indapamide. Its profile
appears to be best described by Figure 4. It is noted below that
this behavior is associated with a striking difference between
indapamide and hydrochlorothiazide with regard to vasodilatory
potential.
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TABLE 2 | The change in human renal hemodynamics after long-term beta-blocker administration.
β-Blockers
Drug References RBF/RPF Pglom GFR FF RVR Duration (weeks) Participant number
Propranolol Ibsen and Sederberg-Olsen, 1973 8–12 11
Falch et al., 1978 2 11 (males)
Falch et al., 1979b 32 13
O’Connor et al., 1979 = 4 12 (males)
Bauer and Brooks, 1979 = 4 8 (normal subjects)
Wilkinson et al., 1980 8 15
Warren et al., 1981 = 4 13
Bauer, 1983 = = = 20–25 14 (males)
Kimura et al., 1988 = 1 8
Malini et al., 1982 = 12 12
O’Connor and Preston, 1982 = = 4 15 (males)
Malini et al., 1984 = = 12 12
van den Meiracker et al., 1989 = = 3 10 (males)
Nadolol O’Connor et al., 1982 = = = =† 6 10 (males)
Textor et al., 1982 = = =† 8 15
O’Callaghan et al., 1983 = = 10 10 (elderly)
Oxprenolol Bellini et al., 1982 = 7 7
Atenolol Wilkinson et al., 1980 = 8 15
Dreslinski et al., 1982 = = 4 10
Bellini et al., 1982 = = 7 7
O’Callaghan et al., 1983 = 12 10 (elderly)
van den Meiracker et al., 1989 = = 3 10 (males)
Samuelsson et al., 1992 = = = = † 4 17
De Cesaris et al., 1993 32 10 (hypertensive diabetics)
Leeman et al., 1993 = = 4 14
Metoprolol Sugino et al., 1984 = = = =† 5–7 9 (males)
Bisoprolol Leeman et al., 1993 = = 4 14
Parrinello et al., 2009 = = =† 52 36
Labetalol Rasmussen and Nielsen, 1981 = 4–15 11
Malini et al., 1982 = 12 12
Participants are individuals with essential hypertension unless otherwise specified. RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR,
renal vascular resistance; , significant decrease from control; , significant increase from control; =, no significant change from control.
†
Apparently anomalous results, given that
for individual subjects RVR = MAP/RBF, MAP falls significantly, and yet neither RBF nor RVR are found to change significantly; the discrepancy arises from the statistical distribution
within the study group.
DISCUSSION
Mechanisms of Afferent Arteriolar
Dilatation
We have observed remarkable similarities of action of several
families of antihypertensive agents that fairly selectively dilate the
afferent arteriole, thereby permitting the kidney to operate at a
new, lower MAP, with indices of renal function downstream of
the afferent arteriole left unchanged (Figure 3). The similarities
of action that follow chronic administration should not
necessarily be taken to imply similarities of mechanism. It is
possible that some agents act as direct vasodilators, whilst others
have indirect effects. Indeed, we have striking evidence of this
being the case as we compare the diuretics with other drugs that
reduce the pressure drop across the afferent arteriole.
A pure directly-acting dilator of the afferent arteriole might
be expected to mimic the consequence of a surgical removal of a
renal artery stenosis and thereby lead to a fall in MAP that does
not depend upon the urinary sodium secretion, as demonstrated
in patients with renovascular hypertension (Kimura et al.,
1987). This phenomenon is depicted in Figure 6 as a parallel
shift downwards of the pressure natriuresis curve, a type of
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FIGURE 4 | The actions on the hydrostatic pressure profile along the
renal vasculature of drugs that primarily redistribute the peritubular
capillary pressure (Ppc) component of the Starling forces across the
tubular epithelium by inhibiting active solute uptake from the renal
tubule. MAP, mean arterial pressure; Pglom, glomerular capillary pressure.
effect that has been confirmed for nicardipine (Kimura et al.,
1988).
A reduction in afferent arteriolar resistance that is
independent of urinary sodium flux might be anticipated for
drugs inhibiting vascular smooth muscle α-adrenoceptors, such
as prazosin and indoramin, drugs reducing sympathetic efferent
activity such as clonidine, moxonidine and α-methyldopa, and
agents having a direct vasodilatory effect on vascular smooth
muscle, such as Ca++-channel blockers. Similarly, given the
known constrictor action on afferent arterioles of angiotensin II
(Wilson, 1986), it is conceivable that a main long-term action of
AR blockers is dilatation of the afferent arterioles. The data of
Table 2 suggest that this effect dominates over the inhibition of
the direct renal tubular actions of angiotensin II (Geibel et al.,
1990) and its action via stimulation of adrenal aldosterone release
(Campbell et al., 1974). That the selective β-blocker atenolol
has a mainly vasodilatory action on the afferent arterioles may
be an indirect effect, secondary to inhibition of renin release
(Wilkinson et al., 1980; Dreslinski et al., 1982; van den Meiracker
et al., 1989) and a resultant decrease in angiotensin levels.
The observation that the chronic action of diuretics is
primarily as afferent arteriolar dilators (Table 4, Figure 3) is
perhaps most surprising of all, given that their main associations
are with tubular sodium uptake mechanisms. Relevant here may
be the known inhibition of macular densa cell function in the
tubulo-arteriolar (also known as tubulo-glomerular) feedback
mechanism by furosemide (Schnermann, 2003; Orlov and
Mongin, 2007) and the recent elucidation of a more distal tubulo-
arteriolar feedback mechanism that can be affected by inhibitors
of the epithelial sodium channel (ENaC), such as amiloride
(Ren et al., 2013; Wang et al., 2015). If the main long-term
action of diuretics were via their inhibition of tubulo-arteriolar
feedback, we would anticipate that the effect would depend upon
sodium flux, with greater dilatation being evident at higher levels
of urinary sodium excretion rate. This appears to be precisely
the phenomenon that is observed with a thiazide, as shown in
Figure 2 (Saito and Kimura, 1996). In Figure 7 we illustrate
the hypothesis that increasing inhibition of tubulo-arteriolar
feedback with increasing sodium excretion may underlie the
reduction in gradient of the pressure-natriuresis line brought
about by a diuretic. It is of interest that a review on thiazides in
2004 started with the statement that “despite their extensive use,
the mechanism by which these drugs lower blood pressure in the
long term remains unknown” and concluded that the most likely
mechanism was via “vasodilator actions” (Hughes, 2004). This
view remains unchanged (Duarte and Cooper-DeHoff, 2010).
Interestingly, a direct vasodilatory action on human systemic
(forearm) vessels of hydrochlorothiazide has been found to be
mediated via potassium channel activation and not by inhibition
of vascular membrane Na-Cl cotransport (Pickkers et al., 1998).
The direct comparison in this study with the thiazide-like drug
indapamide showed the latter to have no vasodilatory effect in
the human forearm, which may help explain why the action of
indapamide in hypertension appears to be mainly via inhibition
of tubular reabsorption, analogous to the action of the non-
selective β-blockers, as depicted in Figure 4.
Relevant to the consideration that inhibitors of membrane
sodium transport may have a substantial direct or indirect effect
on the vasculature is the recent review by Kurtz and colleagues
regarding Mendelian forms of salt-dependent hypertension
(Kurtz et al., 2015). These authors argue that, although it has been
widely assumed that the effects on blood pressure of congenital
renal abnormalities of sodium transport can be attributed to
their actions on extracellular fluid volume, a strong case can
be made for an alternative “vasodysfunction” influencing MAP.
These authors take the view that the pathophysiological action
is via changes in SVR; they do not consider the possibility
that an effect on the renal vasculature may provide the link
between such vasodysfunction and abnormal MAP, a possibility
that we hope this current review might encourage researchers to
explore.
Mechanism for Reduction of Pressure
throughout the Renal Vasculature
The non-selective β-blocking drugs (propranolol, nadolol, and
oxprenolol) appear unique in achieving their hypotensive action
in association with a fall in GFR. They are also distinctive in
reducing RBF and, in some studies, elevating RVR. We argue
above, in relation to Figure 4, that the pressure profile along
the renal vasculature is likely to be lowered throughout by the
drugs. It appears that the dominant action is an inhibition
of solute uptake from the tubule leading to a rebalancing
of Starling forces and a lowering of Ppc. These distinctive
renal hemodynamics focus interest on the β2-adrenoceptors in
the kidney. It is known that different genotypes of the β2-
adrenoceptors are associated with different MAP (Snyder et al.,
2006) and may be associated with hypertension (Kotanko et al.,
1997). One hypothesis for this is that β2 stimulation in the
renal tubule enhances ENaC function (as it does in the lung
alveolar epithelium) and enhances active sodium re-absorption
(Snyder et al., 2005). Another is that the β2 receptor is involved
in aldosterone secretion from adrenal glomerulosa cells (Pojoga
et al., 2006).
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TABLE 3 | The change in human renal hemodynamics after long-term treatment for hypertension with drugs acting on the RAS.
ACE Inhibitors and AR Blockers
Drug References RBF/RPF Pglom GFR FF RVR Duration (weeks) Participant number
Captopril Ando et al., 1986 = 2 12
Shionoiri et al., 1987 = 5–10 days 16
“ 5–10 days 9 (malignant hypertension)
Kimura et al., 1988 = 1 8
Enalapril Simon et al., 1983 16 22
Bauer, 1984; Bauer and Jones, 1984 = = 8 16
“ = 8 10 (subgroup with low GFR)
Katzman et al., 1990 = = = = 8 15
De Cesaris et al., 1993 32 10 (hypertensive diabetics)
Pechere-Bertschi et al., 1998 = = = 6 10
De Rosa et al., 2002 = 156 20
Lisinopril Dupont et al., 1987 = 12 9
Samuelsson et al., 1992 = = = =† 4 17
Degaute et al., 1992 = = = 12 12
Ranieri et al., 1994 12 18
Losartan Paterna et al., 2000 = = 24 18
Inigo et al., 2001 = = = = RA: * 6 17 (renal transplant recipients)
RE: *
De Rosa et al., 2002 156 22
Parrinello et al., 2009 = = =† 52 36
Valsartan Delles et al., 2003 = = = = RA: 8 29
RE: =
Candesartan Fridman et al., 2000 = = 6 19
Participants are individuals with essential hypertension unless otherwise specified. RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR,
renal vascular resistance; , significant decrease from control; , significant increase from control; =, no significant change from control. *Discrepancy between reported result in the
text and in the results table—mistake in decimal point placement in results table assumed (Inigo et al., 2001).
†
Apparently anomalous results, given that for individual subjects RVR =
MAP/RBF, MAP falls significantly, and yet neither RBF nor RVR are found to change significantly; the discrepancy arises from the statistical distribution within the study group.
We noted above that the effect of non-selective β-blocking
drugs is somewhat analogous to a reduction in renal tissue,
despite preservation of normal daily elimination of sodium
and water. One possibility that we have not entertained so
far is an influence of drugs on glomerular mesangial cells.
These smooth-muscle-like cells in the glomerulus have the
potential to reduce the filtration coefficient K and modify
blood flow to the glomerulus (Mene et al., 1989). A wide
variety of signaling systems has been identified in these cells,
including those affected by β-adrenergic agents. One study has
identified a role for β2 stimulation with apoptotic reduction
in cell numbers (Muhl et al., 1996). We should bear in mind,
as we interpret the results of the renal function tests for all
classes of drug, that the association between GFR and Pglom
expressed in Equation (3) involves a permeability coefficient
that is itself under physiological and possibly pharmacological
control.
Kimura et al. examined the effect of sodium excretion rate
on the antihypertensive action of propranolol in hypertensive
patients. In relation to the way we have plotted the pressure-
natriuresis curves in Figure 6, they observed a non-significant
increase in gradient of the line together with a downward shift
of the intercept at zero excretion of 20 mmHg (Kimura et al.,
1988). This suggests that propranolol may have an action on
this relationship that is the opposite of that seen with diuretics,
namely producing a steeper, rather than shallower, pressure-
natriuresis line than that seen before treatment.
Insofar as a non-selective β-blocking drug like propranolol
will have some β1-blocking action like that shown by the selective
agents such as atenolol, we may anticipate that some afferent
arteriolar vasodilatory action will contribute to the lowering
of MAP in Figure 4 in an analogous manner to that seen in
Figure 3.
Mechanisms for Increasing the Pressure
Drop across the Efferent Arteriole
Figure 5 depicts a hydrostatic pressure profile along the renal
vasculature that is consistent with a lowered MAP in the
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presence of a raised GFR. In the case of some Ca++-channel
blockers (amlodipine and manidipine) an increase in RE has
been measured in the presence of an unchanged RBF (Table 1).
The responses of the efferent arterioles to these agents are
clearly very different from the afferent arterioles (Ito and
Abe, 1997). In the case of ACE inhibitors the raised GFR is
associated with an increase in RBF (Table 3); in this case we may
presume that an increase in pressure drop across the efferent
FIGURE 5 | The actions on the hydrostatic pressure profile along the
renal vasculature of drugs that both dilate afferent arterioles and
redistribute the peritubular capillary pressure (Ppc) component of the
Starling forces across the tubular epithelium. These actions lead to a
raised glomerular capillary pressure (Pglom) and a greater pressure drop
across the efferent arterioles, either due to efferent arteriolar constriction or an
increased renal blood flow. MAP, mean arterial pressure.
arteriole may occur even if RE is not raised. Unfortunately, no
individual measurements of RA and RE are reported for ACE
inhibitors.
A question arises as to why the AR blockers appear to have a
somewhat different action on the renal vascular pressure profile
from the ACE inhibitors, given that both agents diminish the
action of angiotensin II. At least three factors seem material:
the AR blockers act on only one of the two main angiotensin
receptors, angiotensin II is formed in part by non-ACE pathways,
and ACE is responsible for breaking down bradykinin—an
endogenous dilator that augments renal blood flow (Epstein and
Gums, 2005).
That the ACE-inhibitor family of drugs has a distinctive effect
on renal function can be illustrated by Kimura’s classification
of diuretic action shown in Figure 6. In a study on captopril a
marked steepening of the gradient of the pressure-natriuresis line
was observed in hypertensives with an approximately fourfold
change in slope (Kimura et al., 1988). This was analogous to the
changes seen with captopril in dogs by Hall et al. (1980). We
might speculate that increasing detachment of the kidney from
control by the renin-angiotensin system makes the pressure-
natriuresis relationship more like that of the unregulated isolated
kidney: a filter requiring ever higher perfusion pressures to
eliminate progressively higher sodium intakes (Kaloyanides et al.,
1971).
Future Directions
Newer experimental approaches to treating hypertension involve
the use of endothelin antagonists (e.g., bosentan), renin
antagonists (e.g., aliskiren), and surgical renal denervation. So
TABLE 4 | The change in human renal hemodynamics after long-term treatment for essential hypertension using diuretics.
Diuretics
Drug References RBF/RPF Pglom GFR FF RVR Duration (weeks) Participant number
Hydrochlorothiazide Van Brummelen et al., 1979 = = = 36 10 (males)
O’Connor et al., 1981;
Warren et al., 1981
= = = 4 19 (males)
Scaglione et al., 1992 = = = 8 13
Chlorothiazide Loon et al., 1989 = = = 4 9
Furosemide Olshan et al., 1981;
Warren et al., 1981
= = = =† 4 12
Spironolactone Falch et al., 1979a = 12 10
Matthesen et al., 2013 = 4 23
Furosemide and spironolactone Loon et al., 1989 = = = 4 6
Amiloride Matthesen et al., 2013 = 4 23
Indapamide Pickkers et al., 1998 = 6 11
RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR, renal vascular resistance; , significant decrease from control; , significant
increase from control; =, no significant change from control.
†
An apparently anomalous result, given that for individual subjects RVR =MAP/RBF, MAP falls significantly, and yet neither
RBF nor RVR are found to change significantly; the discrepancy arises from the statistical distribution within the study group.
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FIGURE 6 | Kimura’s classification of antihypertensive drugs according
to their effects of the pressure-natriuresis relationship. Adapted from
Dorrington and Pandit (2009).
FIGURE 7 | Depiction of the hypothesis that increasing vasodilatory
action of diuretics inhibiting tubulo-arteriolar feedback can account
for the decrease in gradient of the pressure-natriuresis line brought
about by these drugs. A constant degree of afferent arteriolar dilatation leads
to a parallel downward shift of the pressure-natriuresis line (as shown in
Figure 6). The stack of pressure-natriuresis lines depicted here for diuretics
arises because the degree of afferent arteriolar dilatation is hypothesized to
depend upon inhibition tubulo-arteriolar feedback, which in turn depends upon
the sodium excretion rate.
far, these studies have not made the long-term assessment of
human renal hemodynamics a priority, so it is currently not
possible to assess the renal changes brought about with any
precision. Interestingly, a similar paucity of data is evident for
the mode of action of agents that chronically elevate MAP such
as non-steroidal anti-inflammatory drugs, corticosteroids and
alcohol. Furthermore, older antihypertensive agents that had to
some extent fallen out of fashion—such as indapamide (Peters
et al., 2008), amiloride (Brown et al., 2016), hydrochlorothiazide
(MacDonald et al., 2015), and spironolactone (Williams et al.,
2015)—are being found in large trials to have surprising clinical
utility, whilst we continue to remain relatively ignorant about
their renal hemodynamic effects, and therefore their mode of
antihypertensive action. It will be apparent to the reader that
the current authors would very much like to see the collection
of these sorts of data made a priority in future studies of such
agents.
CONCLUSIONS
Drugs proven to have sustained antihypertensive effects have
profound actions on the kidney. These actions are of two
main kinds: dilatation of the afferent arteriole, and inhibition
of solute uptake from the renal tubule. Both actions change
the hydrostatic pressure profile along the renal blood vessels,
the first by changing vascular tone and the second by
rebalancing the contributions to the Starling forces made
by hydrostatic and osmotic pressures driving reabsorption.
Some drugs show both modes of action. The actions of
antihypertensive drugs elsewhere on the body are sometimes
beneficial and often adverse; these actions may be less relevant
to their effects on lowering blood pressure in the long-term,
but much attention is paid to these incidental effects in the
literature.
The literature also reveals striking and often counterintuitive
findings, including that diuretics act as afferent vasodilators,
as do selective β-blockers and AR-blockers. It is remarkable
that the drugs most clearly identifiable as primarily reducing
active sodium reabsorption are those having β2 inhibitory
activity. It remains a challenge to physiology to interpret
the divergent effects of drugs on afferent and efferent
arterioles seen with some Ca++-channel blockers and the ACE
inhibitors.
Though clearly sufficient to permit reasonably firm
conclusions about common renal mechanisms of action
of antihypertensive drugs, studies in humans of the renal
hemodynamic effects over extended periods would benefit
from being more rigorous and numerous. Many have been
motivated by an attempt to display “favorable” renal effects, by
which is usually meant no reduction in GFR or RBF (Textor
et al., 1982; Bauer, 1984; Sugino et al., 1984; Dupont et al.,
1987; Smith et al., 1987; Reams et al., 1988; Degaute et al.,
1992; De Rosa et al., 2002), when it is clear that neither of
these is a prerequisite for clinical efficacy. Furthermore, some
studies misleadingly identify a fall in RVR as contributing
to an antihypertensive effect only in proportion to the
contribution this fall makes to the decrease in overall SVR
(Koshy et al., 1977; Preston et al., 1979; Warren et al., 1981;
Thananopavarn et al., 1982; Bauer, 1984; Dupont et al., 1987;
Smith et al., 1987; van den Meiracker et al., 1989; Fridman
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et al., 2000). The difficulty in humans of identifying the separate
components of the RVR, RA, RE, and RV, has already been
discussed.
The distinctive differences between families of drugs with
regard to their effect on the pressure-natriuresis relationship are
clearly of considerable clinical significance. Information about
the interaction of dietary sodium intake and antihypertensive
medication would be valuable to physicians. Given the huge
importance of antihypertensivemedication, future studies should
seek to determine with greater clarity how these drugs work. In
order to do this effectively, we suggest the focus will by necessity
be on the kidney.
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